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AbsTrACT
Objective We assessed the effect of surgical resection 
of colorectal cancer (crc) on perioperative plasma 
vitamin D (25OHD) and c-reactive protein (crP) level. 
We investigated the relationship between circulating 
vitamin D level and crc survival.
Design We sequentially sampled 92 patients 
undergoing crc resection, and measured plasma 25OHD 
and crP. For survival analyses, we assayed 25OHD and 
crP in two temporally distinct crc patient cohorts 
(n=2006, n=2100) and investigated the association 
between survival outcome, circulating vitamin D and 
systemic inflammatory response.
results Serial sampling revealed a postoperative 
fall (mean 17.3 nmol/l; p=3.6e-9) in plasma 25OHD 
(nadir days 1–2). crP peaked 3–5 days postoperatively 
(143.1 mg/l; p=1.4e-12), yet the postoperative fall in 
25OHD was independent of crP. in cohort analyses, 
25OHD was lower in the 12 months following operation 
(mean=48.8 nmol/l) than preoperatively (54.8 nmol/l; 
p=1.2e-5) recovering after 24 months (52.2 nmol/l; 
p=0.002). Survival analysis in american Joint committee 
on cancer stages i–iii demonstrated associations 
between 25OHD tertile and crc mortality (Hr=0.69; 
95% ci 0.46 to 0.91) and all-cause mortality (Hr=0.68; 
95% ci 0.50 to 0.85), and was independent of crP. We 
observed interaction effects between plasma 25OHD and 
rs11568820 genotype (functional VDR polymorphism) 
with a strong protective effect of higher 25OHD only in 
patients with gg genotype (Hr=0.51; 95% ci 0.21 to 
0.81). We developed an online tool for predicted survival 
(https:// apps. igmm. ed. ac. uk/ mortalitycalculator/) that 
incorporates 25OHD with clinically useful predictive 
performance (area under the curve 0.77).
Conclusions crc surgery induces a fall in circulating 
25OHD. Plasma 25OHD level is a prognostic biomarker 
with low 25OHD associated with poorer survival, 
particularly in those with rs11568820 gg genotype. a 
randomised trial of vitamin D supplementation after crc 
surgery has compelling rationale.
InTrODuCTIOn
Observational studies implicate vitamin D deficiency 
in the aetiology and outcome of several common 
cancers. Available evidence suggests an inverse 
association between circulating 25-hydroxyvitamin 
D (25OHD) and colorectal cancer (CRC) risk and 
outcome.1–4 However, a causal relationship remains 
to be definitively established.5 Mendelian randomi-
sation studies have failed to support a causal infer-
ence.6–8 However, one randomised controlled trial 
to date has shown a beneficial effect of vitamin D 
supplementation on CRC outcome.1 9 10 Absence 
of benefit may reflect inadvertent confounding or 
stratification, low statistical power, inclusion of 
study subjects with sufficient baseline levels, inad-
equate supplementation or insufficient follow-up.11 
It is also possible that the association between 
CRC and vitamin D status is not causal, but 
rather a biomarker of ill health or inflammation.9 
Furthermore, the inverse association could be due 
to reverse causality, with CRC, or its treatment, 
inducing lower vitamin D levels.9 12–15 
significance of this study
What is already known on this subject?
 ► Previous studies indicate that low circulating 
25-hydroxyvitamin D (25OHD) is associated 
with poor colorectal cancer (CRC) survival yet 
sample timing and inflammatory response to 
cancer or surgery may confound these findings.
What are the new findings?
 ► We show that circulating 25OHD falls after 
CRC surgery independent of C-reactive protein 
(CRP), a measure of systemic inflammatory 
response.
 ► We show that the association between low 
vitamin D and adverse outcome in two large 
cohorts is independent of time of sample and 
CRP.
How might it impact on clinical practice in the 
foreseeable future?
 ► Vitamin D level may provide value to existing 
clinicopathological data in survival prediction 
and clinical decision-making.
 ► Vitamin D deficiency is a modifiable risk factor 
associated with survival outcome after CRC 
surgery.
 ► These data support a randomised trial of 
vitamin D after CRC surgery.
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Abdominal surgery is a major physiological insult, yet there 
are no studies of the effect of CRC surgery on circulating vitamin 
D. Published work demonstrates 25OHD (the best marker and 
storage form of vitamin D) decreases following orthopaedic, 
cardiac and gynaecological surgery.14 16–20 Several explana-
tions are proposed to explain the observed changes, including 
circulatory fluid changes, that is, haemodilution19 21 and/or 
systemic inflammatory response (SIR) to surgery. However, 
there is incomplete understanding of the relationship between 
25OHD and C-reactive protein (CRP, an established biomarker 
of inflammation).20
Previous work suggests that 25OHD is associated with 
survival outcome after a diagnosis of CRC.22–28 However, 
such a link may be confounded by the influence of surgery on 
25OHD. Furthermore, there is evidence that the preoperative 
and postoperative inflammatory state itself is associated with 
survival.29 30 Circulating 25OHD has been shown to be associ-
ated with survival in patients with melanoma, independent of 
inflammatory response.31 However, there are no studies to date 
that have investigated the role of inflammation in the relation-
ship between 25OHD and CRC survival.
We set out to investigate temporal variation in circulating 25OHD 
and CRP during the perioperative period by serial sampling of 
patients undergoing CRC resectional surgery. We explored the 
relationship between plasma CRP and 25OHD levels in a cohort 
of patients with CRC previously reported by us22 and conducted 
a replication study in a larger independent cohort. We assayed 
total circulating 25OHD CRP (biomarker of SIR) and genotyped 
individuals for a functional VDR single nucleotide polymorphism 
(SNP) (rs11568820) to investigate gene-environment effects. We 
then conducted multivariable survival analysis in patients with 
CRC undergoing resectional surgery with curative intent to deter-
mine the contribution of 25OHD and CRP to outcome.
MeTHODs
study population
Patients were from the Study of Colorectal Cancer in Scot-
land (SOCCS/SOCCS3) study, a population-based case–control 
study designed to identify genetic and environmental factors 
that have an impact on CRC risk and survival outcome.32 The 
research was subject to approvals from the National Research 
Ethics Committee and National Health Service management. All 
participants provided informed written consent. Clinical vari-
ables were collected from patient clinical records and pathology 
reports. All data were entered into an anonymised prospective 
study database and extracted for analysis.
To explore temporal variation in 25OHD and CRP in the 
perioperative period, we serially sampled 92 patients during 
the preoperative and immediate postoperative period. In the 
prospective observational study, we assayed plasma prospec-
tively collected from two temporally distinct cohorts: cohort 1 
(2001–2006) and cohort 2 (2009–2016) for 25OHD and CRP 
levels.
We excluded patients with metastatic disease at diagnosis 
and conducted survival analysis in patients undergoing resec-
tional surgery with curative intent (American Joint Committee 
on Cancer [AJCC] stages I–III). An updated survival analysis 
was conducted for cohort 1, including extended follow-up data 
and incorporating CRP level to explore whether the previously 
reported association between survival and plasma 25OHD22 was 
independent of SIR. We then set out to replicate the association 
between 25OHD and survival in a larger cohort of patients with 
CRC (cohort 2).
Plasma vitamin D and CrP assay
In the serial sampling study, multiple samples were taken from 
each patient at preoperative assessment clinic intraoperatively 
and postoperatively (ward or outpatient clinic). Participants of 
cohorts 1 and 2 were sampled once at recruitment which was 
at various time points during their cancer investigations or 
follow-up. Prior published data indicated a likely 25OHD drop 
of 30%–40%,17 20 yet SD of the drop is not known. A limited 
paired power calculation suggested that 90 patients would be 
required in the serial sampling study to demonstrate a 30% drop 
(80% power; alpha 0.05).
Plasma was extracted from blood sampled by venepuncture 
and submitted for liquid chromatography tandem mass spec-
trometry measurement of 25OHD at the Specialist Endocrine 
Laboratory (Glasgow Royal Infirmary) and for CRP assay 
at the NHS Lothian Biochemistry Laboratory. Blood leuco-
cyte DNA was extracted by standard protocols and genotyped 
for rs11568820 using an Illumina Infinium array or DNA 
sequencing. Further details on assay, strict quality control and 
genotyping are provided in the online supplementary methods.
Patient, tumour and treatment-related variables
We adjusted statistical models for patient-related factors previ-
ously established to influence 25OHD levels (age, sex, body 
mass index [BMI]) and AJCC stage. Survival data were collated 
from flagging research subjects in the Scottish national records 
system. Follow-up was determined by date of surgery, death or 
censor date (1 July 2017) for patients not known to be dead.
Data analysis
For plasma 25OHD levels below the lower threshold of detection 
level, values were imputed in order to assign a value for inclu-
sion in association analyses (online supplementary methods). 
May adjustment33 to account for seasonable variation in level 
is also described there. Statistical analysis was conducted in R,34 
with univariate comparisons of vitamin D level performed using 
the Wilcoxon signed-rank test.
In the serial sampling study, we tested the association between 
sample time point and 25OHD using multivariable generalised 
linear mixed effects modelling. This model accounts for vari-
ability between patients (ie, assigned as a random effect). In 
cohorts 1 and 2, multivariable linear regression modelling was 
used for single measures of 25OHD to test for association 
between sample time point and 25OHD. Χ2 test was used to 
compare proportions of patients with deficient and sufficient 
levels of 25OHD at different time points. Survival analysis was 
performed using Cox proportional hazards models to calculate 
HRs, adjusting for other relevant factors including CRP and time 
from surgery to sample date. Main effects of the VDR polymor-
phism and its multiplicative interaction with vitamin D level on 
survival were assessed using a Cox proportional hazards model, 
providing a p value for interaction.
Individual cohort survival models excluding, and including, 
vitamin D level were compared using an analysis of variance like-
lihood ratio test with Harrell’s C statistic calculated in R (details 
in online supplementary methods).
resulTs
serial sampling of plasma 25OHD in the perioperative period
A total of 92 patients (table 1) underwent serial periopera-
tive sampling at up to six time points. Mean 25OHD level 
reduced from 48.3 nmol/L preoperatively to 38.2 nmol/L 
intraoperatively (p=0.0004), then 29.0 nmol/L at 1–2 days 
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following surgery (p=3.6e-9, figure 1, table 2). 25OHD 
began to recover within a week of surgery and increased 
to a level above the preoperative level at final sampling 
(64.9 nmol/L), a median of 225 days following surgery. 
Within-subject perioperative 25OHD levels were signifi-
cantly correlated with preoperative levels (eg, day 1–2 level/
preoperative level Spearman correlation R=0.62, p=8.1e-8, 
at all postoperative time points R≥0.62, p<0.0001) indi-
cating that although 25OHD drops postoperatively, the rank 
order of 25OHD levels remained consistent.
To investigate whether the fall in 25OHD level was a mani-
festation of the inflammatory response to surgery, CRP was 
assayed in 70 of the 92 patients (insufficient plasma available for 
remainder). CRP significantly increased after surgery, peaking 
at 3–5 days (mean 143.1 mg/L vs preoperative mean 13.5 mg/L, 
p=1.4e-12; figure 1; online supplementary table 1). However, 
there was no correlation between 25OHD and CRP levels at 
any early postoperative time point (R2<0.015, p≥0.5) and the 
fall in 25OHD was not correlated with concurrent increase in 
CRP (R2<0.02, p≥0.38). Adjusting for the 3–5 days’ lag in CRP 
increase, compared with the fall in 25OHD at 1–2 days, simi-
larly revealed no apparent correlation. Using generalised linear 
mixed effects modelling, we observed significantly lower 25OHD 
for up to 120 days after surgery, even after adjustment for CRP 
(online supplementary table 2). This strongly suggests that the 
fall in plasma vitamin D level is independent of postsurgical SIR.
25OHD level and survival outcome in CrC patient cohorts
We assessed trends in 25OHD level over time from surgery 
with respect to survival (figure 2, table 1). We observed 
Table 1 Clinical characteristics of included patients
serial sampling study
Cohort study
Time point analysis
Cohort study
survival analysis
Cohort 1 Cohort 2 Cohort 1 Cohort 2
n 92 2006 2100 1687 1848
Sampling years 2012–2016 2001–2006 2009–2017 2001–2006 2009–2017
Age (years) 67.1 (64.4–69.9) 60.1 (60.6–61.6) 67.2 (66.7–67.7) 61.5 (61.0–62.0) 67.6 (67.1–68.1)
Gender (M) 51 (55%) 1137 (57%) 1172 (56%) 970 (57%) 1024 (55%)
BMI (kg/m2) 26.1 (24.8–27.5) 26.6 (26.4–26.8) 27.5 (27.3–27.7) 26.6 (26.4–26.8) 27.6 (27.4–27.9)
Cancer site
  Colon 62 (67%) 1153 (57%) 1313 (63%) 962 (57%) 1161 (63%)
  Rectum 30 (33%) 829 (41%) 761 (36%) 714 (42%) 687 (37%)
  NA 0 24 (1%) 56 (3%) 11 (1%) 0 (0%)
Cancer stage
  AJCC 1 27 (29%) 383 (19%) 415 (20%) 383 (22%) 415 (22%)
  AJCC 2 31 (34%) 666 (33%) 692 (33%) 666 (39%) 692 (37%)
  AJCC 3 21 (23%) 638 (32%) 741 (35%) 638 (38%) 741 (40%)
  AJCC 4 7 (8%) 268 (13%) 167 (8%) 0† 0†
  NA 6 (7%) 51 (3%) 85 (4%) 0 0
‘raw’ 25OHD (nmol/L) NA* 29.3 (28.4–30.2) 46.5 (45.3–47.6) 29.1 (28.1–30.1) 46.0 (44.7–47.4)
May-adjusted 25OHD 
(nmol/L)
NA* 33.9 (33.0–34.8) 51.7 (50.5–52.8) 28.8 (27.82–29.7) 52.1 (50.9–53.4)
  Tertile 1 NA* <18.5 <37.32 <18.1 <38.0
  Tertile 2 NA* 18.5–34.0 37.3–56.5 18.1–33.1 38.0–57.9
  Tertile 3 NA* >34.0 >56.46 >33.1 >57.9
Sample time point
  Preoperative (months) NA* 0 (0%) 560 (27%) 0 (0%) 486 (26%)
  0–12 NA* 1798 (90%) 549 (26%) 1517 (90%) 471 (26%)
  12–24 NA* 180 (9%) 396 (19%) 147 (9%) 351 (19%)
  >24 NA* 28 (1%) 595 (28%) 23 (1%) 540 (29%)
Season of sample
  Winter NA* 489 (24%) 573 (27%) 408 (24%) 517 (28%)
  Spring NA* 524 (26%) 563 (27%) 449 (27%) 483 (26%)
  Summer NA* 465 (23%) 434 (21%) 392 (23%) 378 (20%)
  Autumn NA* 528 (26%) 530 (25%) 438 (26%) 470 (25%)
Follow-up (days) NA* NA NA 4841 1318
Survival
  Alive NA* NA NA 978 (58%) 1637 (89%)
  Dead NA* NA NA 709 (42%) 211 (11%)
  CRC death NA* NA NA 421 (25%) 138 (7%)
Age at time of surgery given. Pre-illness BMI reported where available. Mean values given for summary variables except follow-up (median censored follow-up given). ‘Raw’ 
25OHD was not adjusted for seasonal variation, that is, not ‘May-adjusted’.
*Repeated measures.
†AJCC 4 excluded from survival analysis.
25OHD, 25-hydroxyvitamin D; AJCC, American Joint Committee on Cancer; BMI, body mass index; CRC, C-reactive protein; NA, not applicable. 
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associations between 25OHD level and age, BMI and AJCC 
stage (online supplementary table 3). There was a trend towards 
increase in mean 25OHD over time from surgery in cohort 
1 (figure 3, online supplementary table 4). In cohort 2, mean 
25OHD was significantly lower in samples taken 0–12 months 
following surgery (48.8 nmol/L) when compared with preoper-
ative samples (54.8 nmol/L; p=1.2e-5) and late postoperative 
samples (>24 months, 52.2 nmol/L; p=0.002) (online supple-
mentary table 4, figure 3), consistent with a pattern of postoper-
ative fall and then recovery in 25OHD similar to that seen in the 
serial sampling study described above.
25OHD level, CrP and survival following CrC surgery
Plasma CRP was assayed in parallel with 25OHD in samples 
obtained from 1798 patients with CRC (404 preoperative 
cases from cohort 2, 1273 within 12 months of surgery and 
121 cases >12 months from surgery from cohort 1). 25OHD 
and CRP were weakly correlated at all time points (preoper-
ative samples R=−0.12, p=0.02; 0–12 months R=−0.14, 
p=1.2e-6; >12 months R=−0.16, p=0.03), with no clear 
difference in the strength of the correlation between 25OHD 
and CRP between the sampling time point categories, suggesting 
that the early postsurgical inflammatory response does not influ-
ence the weak observed association between 25OHD and CRP.
Survival data were analysed for cohort 1 and cohort 2 patients 
who underwent surgical resection with curative intent with 
follow-up data available for analyses (table 1, figure 2).
Cohort 1 patients (n=1687) had a median follow-up of 
13.3 years, with 709 deaths (421 CRC-specific deaths). Some 
1223 patients had contemporaneously sampled CRP (mean 3.52, 
median 98 days postoperative), with the majority <10 mg/L 
(92%). Survival analysis adjusting for CRP level showed that 
higher postoperative 25OHD levels were independently asso-
ciated with lower CRC-specific mortality (p=0.007) and 
all-cause mortality (p=0.0002; 25OHD as continuous variable). 
Comparing patients with May-adjusted 25OHD levels in the 
highest versus the lowest tertile, the fully adjusted HR (including 
adjustment for CRP) was 0.66 (95% CI 0.49 to 0.89) for 
CRC-specific mortality and 0.65 (95% CI 0.51 to 0.81) (table 3) 
for all-cause mortality, indicating that postoperative 25OHD 
influences survival outcome after a diagnosis of CRC indepen-
dent of sample time point and the inflammatory response.
To further explore these findings, we sought to replicate the 
association between plasma 25OHD and survival. We conducted 
further analysis in cohort 2 (n=1848, median follow-up 
3.6 years, range 52 days to 15 years), in which 211 deaths had 
occurred (138 CRC specific). Comparing patients with May-ad-
justed 25OHD levels in the highest versus the lowest tertile, the 
fully adjusted HR was 0.62 (95% CI 0.40 to 0.95) for CRC-spe-
cific mortality and 0.63 (95% CI 0.44 to 0.89) for all-cause 
mortality, thereby further strengthening previous findings in 
cohort 1 (table 3).
Sensitivity analyses indicated that 25OHD was most strongly 
associated with survival of those patients sampled preop-
eratively (HR=0.30 all-cause death, 95% CI 0.12 to 0.71, 
online supplementary table 5). In cohort 2 patients assayed 
for CRP (all sampled preoperatively), 25OHD was again inde-
pendently associated with all-cause mortality (tertile 3 vs tertile 
1 HR=0.38, 95% CI 0.15 to 0.98) (online supplementary table 
6). Finally, we undertook a recursive approach with 25OHD as 
a categorical threshold variable, in which a 25OHD threshold 
of ~45–50 nmol/L appears to most strongly associate with 
survival when considering both effect size and significance 
(online supplementary table 7).
Meta-analysis of survival outcome
We observed a cohort effect on mean vitamin D levels between 
cohorts 1 and 2 (mean 25OHD 28.8 and 52.1 nmol/L), 
despite rigorous internal controls in the assay labora-
tory. Despite this, meta-analysis demonstrates associations 
80
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Figure 1 Perioperative 25OHD and CRP in patients undergoing 
colorectal cancer surgery. Unadjusted 25OHD charted with CRP. 
Sixty-two patients undergoing colorectal cancer surgery sampled at 
up to six perioperative time points. Mean 25OHD and CRP for each 
time point category given with error bars representing SD. 25OHD, 
25-hydroxyvitamin D; CRP, C-reactive protein. 
Table 2 May-adjusted 25OHD level in serial sampling study
Time point n 25OHD (nmol/l) Difference (nmol/l) P value* P value†
Preoperative 92 48.3 (43.3–53.4) Reference Reference Reference
Intraoperative 30 38.2 (31.8–44.7) −12.8 0.0004 7.8e-5
1–2 62 29.0 (25.1–32.9) −17.3 3.6e-9 5.5e-7
3–5 58 29.6 (25.2–34.1) −17.2 4.4e-9 6.5e-5
6–9 45 35.0 (28.7–41.2) −12.7 3.0e-6 0.002
30–120 58 40.0 (34.4–45.5) −6.4 0.002 0.04
>162 40 64.9 (53.5–76.2) 18.3 3.1e-5 2.0e-8
Difference in 25OHD at each time point accounts for missing samples within paired comparisons. Preoperative samples were taken median 7.5 days before surgery (range 49 to 
0 day). >162 day samples taken median 225 days postoperatively (range 163–315 days).
*P values given represent paired Wilcoxon sign-rank test results with preoperative level as reference. C-reactive protein (CRP) was assayed in 70 patients preoperatively. Of these, 30 then 
had repeat CRP assayed in intraoperative samples while 40 patients had CRP assayed at various postoperative time points.
†P values given represent results from linear mixed model including the fixed covariates age, gender, body mass index (BMI) and CRP, and patient ID included as a random effect.
25OHD, 25-hydroxyvitamin D. 
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between May-adjusted 25OHD and both CRC-specific 
(tertile 3 vs tertile 1; HR=0.69, 95% CI 0.46 to 0.91) and 
overall survival (HR 0.68, 95% CI 0.50 to 0.85; figure 4) 
that are clinically meaningful. Meta-analysis of patients with 
contemporaneous CRP assay confirmed association with 
CRC-specific (HR=0.66, 95% CI 0.38 to 0.95) and all-cause 
mortality (HR=0.64 95% CI 0.42 to 0.85) independent of 
the SIR (online supplementary figure 1).
Although the higher 25OHD level in the more recent 
cohort may result from sample collection/storage/transporta-
tion factors, natural variability between/within study subjects, 
publicity about vitamin D leading to increased availability/
ingestion of supplements and foodstuffs or differential sun 
exposure over time might have results in a true biological 
difference in level between the two cohorts. Therefore, we 
performed an adjusted survival analysis, comparing survival 
in cohort 1 vs cohort 2 irrespective of actual 25OHD level, 
which showed significantly improved cancer-specific and 
overall survival in cohort 2 (HR=0.58, 95% CI 0.42 to 0.79 
and HR=0.63, 95% CI 0.49 to 0.80, online supplementary 
table 8).
Genotype at the rs11568820 VDr locus snP and survival
We confirmed previously reported evidence for gene–environ-
ment interaction effects on CRC-specific mortality between 
25OHD level and genotype at a functional variant within the 
VDR gene sequence (rs11568820)22 in cohort 1, p=0.02. This 
remained significant after adjustment for CRP level (interac-
tion p=0.003), and replicated this G×E in cohort 2 (interac-
tion p=0.03) (online supplementary table 9). A meta-analysis of 
survival outcome stratified by genotype at rs11568820 supports 
the genetic interaction with vitamin D on survival. The asso-
ciation between 25OHD level and survival was particularly 
strong for the GG genotype (tertile 3 vs tertile 1 HR for CRC 
mortality in rs11568820 AA/AG HR=1.09; 95% CI 0.72 to 
1.46; rs11568820 GG genotype HR=0.51; 95% CI 0.21 to 
0.81, figure 5, online supplementary table 10). This observed 
COHORT 1 COHORT 2
2765 CRC cases
No surgical resection
n=574 (21%)
Plasma not available for LCMS assay
n=154 (6%)
Technical assay failure
n=11 (0.5%)
Operative details incomplete
n=20 (1%)
AJCC stage 4 n=268 (13%)
Tx and/or Nx and/or Mx
n=51 (3%)
AJCC stage 4 n=167 (8%)
Tx and/or Nx and/or Mx
n=85 (4%)
Plasma from 2037 cases
submitted for 250HD analysis
Clinical and operative details
examined for 2026 cases
No surgical resection
n=526 (19%)
Plasma not available for LCMS assay
n=47 (2%)
Technical assay failure
n=31 (1%)
Plasma from 2131 cases
submitted for 250HD analysis
Clinical and operative details
examined for 2026 cases
CRC cohort 1
N=2006Timepoint analysis
CRC cohort 2
N=2100
CRC cohort 1
N=1687Survival analysis
CRC cohort 2
N=1848
2704 CRC cases
Figure 2 Flow chart of study participants. Patients were sampled from the Scottish colorectal cancer study from 2000 to 2006 (cohort 1) and from 
2009 to 2017 (cohort 2, recruited up to 23 February 2017). *Tx and/or Nx and/or Mx indicates pathology report and AJCC stage not available, AJCC 
stage 4 indicates stage at time of surgery. Cohort 2 recruited and assayed up to 23 February2017. 25OHD, 25-hydroxyvitamin D; AJCC, American Joint 
Committee on Cancer; CRC, C-reactive protein; LCMS, liquid chromatography–mass spectrometry.  on
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G×E effect supports a causal association between vitamin D and 
survival outcome.
survival modelling and assessment of 25OHD clinical utility in 
prognosis
Comparison of the Cox proportional hazards models with/
without 25OHD level found a modest improvement in the 
survival model including 25OHD level (likelihood ratio test 
p=2.9e-5, Harrell’s C statistic with/without 25OHD 0.67 and 
0.66), indicating potential value of vitamin in survival prediction 
and clinical decision-making. Harrell’s C statistic was highest for 
preoperatively sampled patients (0.81) despite a relatively small 
sample size (n=451). To provide a clinically relevant model, we 
constructed a proof of concept logistic regression survival model 
based on survival at follow-up truncated 5 years (online supple-
mentary table 11). Unadjusted 25OHD was modelled with 
sample month and sample time point (</>12 months following 
surgery), age, gender, cancer site and AJCC as covariates. In the 
model, 25OHD as a continuous variable was significantly asso-
ciated with survival in both cohorts (cohort 1 p=0.02; cohort 
2 p=0.015), with a significant and clinically relevant uplift in 
area under the curve (AUC) seen with inclusion of 25OHD in 
the model (cohort 2 AUC excluding/including 25OHD level 
0.74 and 0.77, respectively; online supplementary table 12). The 
cohort 2 model for survival prediction at 5 years was published 
at https:// apps. igmm. ed. ac. uk/ mortalityCalculator/ with cohort 
2 chosen as it represents a more up-to-date population with 
greater spread of perioperative 25OHD sampling.
DIsCussIOn
Serial sampling of patients undergoing resectional surgery 
for CRC demonstrates that surgery induces a fall in plasma 
vitamin D level, independent of CRP response. Plasma 25OHD 
levels sampled soon after surgery are lower when compared with 
those sampled later, consistent with a postoperative drop and 
longer term recovery in 25OHD. We found strong evidence of an 
association between lower vitamin D levels and adverse survival 
outcome in both cohorts and this association was independent 
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Figure 3 Difference in May-adjusted 25OHD levels by sample 
time point in cohorts. Mean May-adjusted 25OHD level at 0–12 months’ 
time point used as reference. 25OHD values scaled against reference 
mean and mean difference for each time point category given with error 
bars representing SEM. Cohort 1 (n=2006), cohort 2 (n=2100). 25OHD, 
25-hydroxyvitamin D; CRC, C-reactive protein. 
Table 3 Unadjusted and multivariable adjusted HRs of death in cohort 1 and cohort 2 according to May-adjusted 25OHD tertile
Model n
Cohort 1
Tertile 1
<18.1 nmol/l
Tertile 2
18.1–33.1 nmol/l
Tertile 3
>33.1 nmol/l
PtrendHr Hr 95% CI P value Hr 95% CI P value
CRC death
Model 1* 1685 Ref 0.84 0.67 to 1.06 0.15 0.74 0.58 to 0.93 0.01 0.05
Model 2† 1486 Ref 0.85 0.67 to 1.09 0.20 0.71 0.55 to 0.92 0.01 0.03
Model 3‡ 1058 ref 0.77 0.59 to 1.04 0.09 0.66 0.49 to 0.89 0.006 0.007
All death
Model 1* 1685 Ref 0.77 0.65 to 0.92 0.004 0.70 0.58 to 0.84 0.0001 0.0006
Model 2† 1486 Ref 0.77 0.64 to 0.92 0.005 0.69 0.56 to 0.84 0.0002 0.0004
Model 3‡ 1058 ref 0.72 0.58 to 0.91 0.006 0.65 0.51 to 0.81 0.0002 0.0002
n
Cohort 2
Tertile 1
<38.0 nmol/l
Tertile 2
38.0–57.9 nmol/l
Tertile 3
>57.9 nmol/l
PtrendCRC death Hr Hr 95% CI P value Hr 95% CI P value
Model 1* 1844 Ref 0.70 0.47 to 1.04 0.08 0.56 0.37 to 0.86 0.008 0.10
Model 2† 1792 ref 0.77 0.52 to 1.13 0.19 0.62 0.40 to 0.95 0.03 0.13
All death
Model1* 1844 Ref 0.76 0.55 to 1.04 0.09 0.58 0.41 to 0.82 0.002 0.04
Model 2† 1792 ref 0.84 0.61 to 1.15 0.27 0.63 0.44 to 0.89 0.01 0.08
Final model is shown in bold.
*Model adjusted for age, sex and American Joint Committee on Cancer (AJCC) stage.
†Multivariable model additionally adjusted for body mass index, tumour site (colon/rectum), time between definitive treatment and sampling. Where data were missing, 
participants were excluded from adjusted model reflected in decreasing numbers of patients included in each sequential model.
‡Multivariable model additionally adjusted for C-reactive protein (CRP) which is not displayed for cohort 2 as only a small subset had CRP assayed. Trend—25OHD as a 
continuous variable. Adjustment of model 3 for dietary intake of vitamin D or vitamin D supplementation did not substantially alter observed HRs.
25OHD, 25-hydroxyvitamin D; CRC, colorectal cancer. 
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of the SIR (as reflected by CRP). Furthermore, there is a strong 
genotype-specific effect of vitamin D, with survival association 
greatest in those with the VDR rs11568820 GG genotype. The 
findings have potential clinical relevance in survival prediction 
and clinical decision-making. While the mechanism underlying 
this observed association merits further study, this study supports 
the notion that vitamin D is a modifiable risk factor for survival 
outcome and provides compelling rationale for an intervention 
trial of supplementation after CRC surgery.
It is argued that the association between 25OHD and CRC 
risk/survival might reflect the influence of the SIR to CRC or its 
treatment on 25OHD.9 15 Indeed, CRP, a marker of inflamma-
tion, is also correlated with both CRC risk35 and survival.29 36 
However, the current study provides evidence against CRP as 
a confounding variable in observational studies of 25OHD and 
CRC risk/outcome. First, the contribution to the variance 
of 25OHD by SIR is small. Second, we found no correlation 
between 25OHD drop following surgery and concurrent CRP 
increase while the postoperative drop in 25OHD was inde-
pendent of changes in CRP, consistent with similar periopera-
tive studies.14 20 Finally, 25OHD level was associated with both 
CRC and all-cause mortality, even after adjustment for CRP, 
supporting similar findings in patients with melanoma.31 Indeed, 
the relationship between postoperative 25OHD and survival 
appears stronger (effect size and greater statistical significance) 
after adjustment for CRP, despite smaller number of patients in 
adjusted analysis. Thus, after any variance in outcome explained 
by CRP is accounted for, the relationship between 25OHD and 
outcome becomes more apparent, providing further support for 
the independent effect of vitamin D on CRC survival.
Lower 25OHD levels are associated with higher CRC-specific 
and all-cause mortality even after adjustment for CRP and sample 
time from surgery. This survival association is consistent with 
numerous previous studies2 and indicates that plasma 25OHD 
level may be useful as a biomarker predicting survival outcome. 
We have developed a survival model including plasma 25OHD 
level with a clinically useful predictive performance (available at 
Figure 4 Meta-analysis of HR of 25OHD tertile 3 versus tertile 1 with 
colorectal cancer (CRC)-specific and all-cause mortality. Adjusted HRs 
used for meta-analysis, adjusted for age, sex, American Joint Committee 
on Cancer (AJCC) stage, body mass index, tumour site (colon/
rectum) and time between definitive treatment and sampling. 25OHD, 
25-hydroxyvitamin D; CRP, C-reactive protein. 
Figure 5 Meta-analysis of HR of 25OHD tertile 3 versus tertile 1 for 
colorectal cancer (CRC) mortality stratified by rs11568820 genotype. 
Adjusted HRs used for meta-analysis, adjusted for age, sex, American 
Joint Committee on Cancer (AJCC) stage, body mass index, tumour 
site (colon/rectum) and time between definitive treatment and 
sampling. 25OHD, 25-hydroxyvitamin D; CRP, C-reactive protein. 
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https:// apps. igmm. ed. ac. uk/ mortalityCalculator/). Furthermore, 
we have seen a strong genotype-specific effect of vitamin D, with 
survival association greatest in those with the VDR rs11568820 
GG genotype. The combined HR in these patients is 0.51 
(95% CI 0.21 to 0.81), indicating double the risk of CRC-spe-
cific death in patients with the lowest tertile of 25OHD. The 
rs11568820 variant is located in the VDR promoter region and 
directly inﬂuences transcriptional activity37 providing biological 
plausibility to this clinically relevant genotype-specific effect.
Limitations of this study include the possibility that unmea-
sured differences in demographics, genetic background or clin-
ical factors might explain the observed differences in 25OHD. 
Second, 25OHD levels were different between the two cohorts. 
This may indicate real biological differences or could reflect 
differences in sample handling. The better survival in cohort 2 
when compared with cohort 1 may reflect the improved vitamin 
D status in these patients due to the reasons stated above, yet 
may be partially or wholly explicable by advances in surgical, 
perioperative and oncological practice. To address these issues 
we have performed per-cohort analyses and meta-analysis. 
Finally, we cannot exclude the possibility that the perioperative 
drop in 25OHD is due to factors other than surgery itself (eg, 
anaesthetic, period of starvation).
Our data indicate that observed associations between 25OHD 
and CRC outcome are independent of the inflammatory response 
to CRC or its treatment and suggest that 25OHD level could 
be of utility in clinical decision-making, with the survival model 
provided here now meriting further validation. The observed 
gene interaction between 25OHD level and VDR genotype is 
consistent with a causal relationship between vitamin D and 
survival in patients with CRC. This study establishes that vitamin 
D deficiency is a modifiable risk factor associated with survival 
outcome from CRC. The findings provide compelling rationale 
for a randomised trial of vitamin D supplementation of deficient 
patients after CRC surgery with a defined endpoint of survival.
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